The transcript encoding antizyme inhibitor 1 (AZIN1) is frequently edited in various cancers, and this editing is associated with enhanced tumor aggressiveness. Creative Biolabs provides a comprehensive set of AZIN1 analysis services for global clients. Whether your study is performed as part of an integrated package or as stand-alone analytical options, our focus on strategic assay validation/qualification enables us to accurately test your study samples and provide reliable biological translation to your drug discovery program.
Introduction
Adenosine (A) to inosine (I) RNA editing catalyzed by ADAR enzymes is a post-transcriptional modification (PTM) that emerged as a key player in tumorigenesis and cancer progression. AZIN1 belongs to the antizyme inhibitor family and plays role in maintaining polyamine homeostasis which is important for various cellular functions. AZIN1 is one of the most frequent A-to-I RNA alterations in many human cancers including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and prostate cancers. High levels of AZIN1 RNA editing emerged as a prognostic factor for overall survival and disease-free survival and were an independent risk factor for lymph nodes and distant metastasis.
Fig.1 AZIN1 and cancer development.1
Could AZIN1 Become a Critical Target for Anticancer Therapy?
AZIN1 has been shown to have more functions outside the polyamine pathway to bypass the deficiency of targeting the polyamine biosynthetic pathway. Thus, Creative Biolabs has sufficient reasons to believe that targeting AZIN1 for cancer therapy may be a better strategy since such a treatment would affect cell proliferation not only through the polyamine pathway but also through additional mediators.
We Have Your Biomarker Assay Needs Covered
AZIN1 is one of the best studied ADAR1 targets in cancer. For instance, editing of AZIN1 results in a serine (S) to glycine (G) substitution at residue 367, and the edited form AZIN1S367G is more stable and has a stronger affinity to antizyme than AZIN1wild-type. The degree of editing of AZIN1 RNA could be analyzed using the RNA editing site-specific quantitative PCR (RESSq-PCR). Besides, the AZIN1-antizyme binding affinity could be measured by a FRET assay. Creative Biolabs has also developed antibodies raised against a recombinant fusion protein containing sequences corresponding to different fragments of human/mouse/rat AZIN1. Antibodies can be used in various scientific applications, including WB, IHC, ICC, and ELISA. Our major services include but are not limited to the following:
- Total RNA extraction and cDNA synthesis
- RESSq-PCR
- RP-qPCR
- Generation of the un-editable AZIN1 construct
- FRET assay
- Co-IP
- IHC
In recent years, AZIN1 has aroused more attention because of its contribution to cancer. If you are looking for AZIN1 analysis, please contact us for more information.
Reference
- Wei, Yan, et al. "A novel mechanism for A-to-I RNA-edited AZIN1 in promoting tumor angiogenesis in colorectal cancer." Cell death & disease 13.4 (2022): 294. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
